PL3368512T3 - Pochodne indoliny do leczenia i/albo zapobiegania chorobie zwłóknieniowej - Google Patents

Pochodne indoliny do leczenia i/albo zapobiegania chorobie zwłóknieniowej

Info

Publication number
PL3368512T3
PL3368512T3 PL15907425.1T PL15907425T PL3368512T3 PL 3368512 T3 PL3368512 T3 PL 3368512T3 PL 15907425 T PL15907425 T PL 15907425T PL 3368512 T3 PL3368512 T3 PL 3368512T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
indoline derivatives
fibrosis diseases
fibrosis
Prior art date
Application number
PL15907425.1T
Other languages
English (en)
Inventor
Chien Huang Lin
Jing Ping Liou
Shiow-Lin Pan
Che-Ming Teng
Original Assignee
Taipei Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taipei Medical University filed Critical Taipei Medical University
Publication of PL3368512T3 publication Critical patent/PL3368512T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PL15907425.1T 2015-10-27 2015-10-27 Pochodne indoliny do leczenia i/albo zapobiegania chorobie zwłóknieniowej PL3368512T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/057600 WO2017074317A1 (en) 2015-10-27 2015-10-27 Indoline derivatives for treatment and/or prevention of fibrosis diseases

Publications (1)

Publication Number Publication Date
PL3368512T3 true PL3368512T3 (pl) 2024-05-27

Family

ID=58630805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15907425.1T PL3368512T3 (pl) 2015-10-27 2015-10-27 Pochodne indoliny do leczenia i/albo zapobiegania chorobie zwłóknieniowej

Country Status (11)

Country Link
US (2) US11278523B2 (pl)
EP (1) EP3368512B1 (pl)
JP (2) JP7302120B2 (pl)
CN (2) CN116077489A (pl)
ES (1) ES2965877T3 (pl)
HR (1) HRP20240306T1 (pl)
HU (1) HUE065418T2 (pl)
PL (1) PL3368512T3 (pl)
RS (1) RS65201B1 (pl)
TW (1) TWI663973B (pl)
WO (1) WO2017074317A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965877T3 (es) * 2015-10-27 2024-04-17 Univ Taipei Medical Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
JP2026506594A (ja) * 2023-02-09 2026-02-25 アンボーゲン セラピューティクス インコーポレイテッド 大腸癌の治療のための医薬キット及びその使用
US20250011283A1 (en) * 2023-06-27 2025-01-09 Chuan Shih Crystalline forms of (e)-n-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842525B1 (fr) * 2002-07-16 2005-05-13 Aventis Pharma Sa Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2409756T3 (es) 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
EP2100879A1 (en) * 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
US9296692B2 (en) * 2011-09-15 2016-03-29 Taipei Medical University Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
CN107099581B (zh) 2012-03-27 2021-07-13 弗·哈夫曼-拉罗切有限公司 预测、诊断和治疗特发性肺纤维化的方法
US9718760B2 (en) * 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
CA2931345A1 (en) 2013-11-24 2015-05-28 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
US20150368195A1 (en) * 2014-06-20 2015-12-24 Taipei Medical University Indoline compounds for treatment and/or prevention of inflammation diseases
ES2965877T3 (es) * 2015-10-27 2024-04-17 Univ Taipei Medical Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
KR102410951B1 (ko) * 2016-04-11 2022-06-20 장피트 담즙정체성 및 섬유증 질환의 치료 방법
US12011475B2 (en) * 2017-03-01 2024-06-18 Chengdu Huitai Biomedicine Co., Ltd. Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN115192714B (zh) * 2022-07-08 2024-09-17 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途

Also Published As

Publication number Publication date
US11278523B2 (en) 2022-03-22
CN108368043B (zh) 2022-11-29
RS65201B1 (sr) 2024-03-29
ES2965877T3 (es) 2024-04-17
EP3368512A1 (en) 2018-09-05
US20180243264A1 (en) 2018-08-30
HUE065418T2 (hu) 2024-05-28
EP3368512B1 (en) 2023-12-06
TW201714614A (zh) 2017-05-01
JP2021119190A (ja) 2021-08-12
EP3368512C0 (en) 2023-12-06
JP2018531959A (ja) 2018-11-01
JP7723400B2 (ja) 2025-08-14
TWI663973B (zh) 2019-07-01
HRP20240306T1 (hr) 2024-05-10
US20220184032A1 (en) 2022-06-16
CN116077489A (zh) 2023-05-09
EP3368512A4 (en) 2019-06-26
WO2017074317A1 (en) 2017-05-04
CN108368043A (zh) 2018-08-03
JP7302120B2 (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL250960B (en) Combined treatment of sinecriviroc for the treatment of leprosy
EP3142707A4 (en) Methods and compositions for prevention or treatment of a disease
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
IL266047A (en) Methods and preparations for the treatment of Fabry disease
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
IL264451B1 (en) A combination of abt-199 and achmetalstat for the treatment of aml
LT3157531T (lt) Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti
SG10201402819WA (en) Composition for prevention and treatment of joint pain and the method of preparation thereof
IL253854A0 (en) A polymorph of mebendazole for the treatment and prevention of tumors
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
EP3263114A4 (en) Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome
EP3107534A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
IL257336B (en) Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases
ZA201900984B (en) Methods and compositions for the treatment of warts
HUE065418T2 (hu) Indolin származékok fibrózisos betegségek kezelésére és/vagy megelõzésére
ZA201706985B (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
EP3371154A4 (en) HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
IL251135A0 (en) A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
EP3284475A4 (en) Agent for prevention or treatment of corneal disorders
EP3267992A4 (en) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases